Global Alliance for TB Drug Development:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Global Alliance for TB Drug Development - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9271
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:24
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Global Alliance for TB Drug Development (TB Alliance) is a non-profit organization that discovers and develops drugs to treat tuberculosis. The organization’s products include natural products, rifampin, pyrazinamide, isoniazid, macrokuds, ethambutol, and topoisomerase inhibitors. It offers biomakers and lab manuals products for the treatment against susceptible and resistant strains with antiretroviral therapies for HIV-TB patients. TB Alliance also provides community engagement programs that promote better understanding of TB disease and research. The organization partners with academic institutions, pharmaceutical developers, and research institute. It operates through pre-clinical and clinical development in the US and South Africa. TB Alliance is headquartered in New York, the US.

Global Alliance for TB Drug Development – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Global Alliance for TB Drug Development, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Global Alliance for TB Drug Development, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Global Alliance for TB Drug Development, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Global Alliance for TB Drug Development, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Global Alliance for TB Drug Development, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Global Alliance for TB Drug Development, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
Astellas Pharma Enters into Agreement with TB Alliance 10
TB Alliance and Takeda Pharma Enter into Agreement 11
Shionogi to Enter into Agreement with TB Alliance 12
Sanofi Enters Into Research Agreement With TB Alliance To Advance Treatments For Tuberculosis 13
CSIR Enters Into Co-Development Agreement With TB Alliance 14
Licensing Agreements 15
TB Alliance Enters into Licensing Agreement with Medicines Patent Pool 15
Novartis Enters into Licensing Agreement with Global Alliance for TB Drug Development for Tuberculosis Drugs 16
TB Alliance Enters Into Licensing Agreement With Fosun Pharma 17
Asset Transactions 18
TenNor Acquires Patents from TB Alliance 18
Global Alliance for TB Drug Development – Key Competitors 19
Global Alliance for TB Drug Development – Key Employees 20
Global Alliance for TB Drug Development – Locations And Subsidiaries 22
Head Office 22
Other Locations & Subsidiaries 22
Recent Developments 23
Corporate Communications 23
Mar 06, 2018: Nancy Miller-Rich Joins TB Alliance Board of Directors 23
Appendix 24
Methodology 24
About GlobalData 24
Contact Us 24
Disclaimer 24

List of Tables
Global Alliance for TB Drug Development, Pharmaceuticals & Healthcare, Key Facts 2
Global Alliance for TB Drug Development, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Global Alliance for TB Drug Development, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Global Alliance for TB Drug Development, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Global Alliance for TB Drug Development, Deals By Therapy Area, 2012 to YTD 2018 8
Global Alliance for TB Drug Development, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Astellas Pharma Enters into Agreement with TB Alliance 10
TB Alliance and Takeda Pharma Enter into Agreement 11
Shionogi to Enter into Agreement with TB Alliance 12
Sanofi Enters Into Research Agreement With TB Alliance To Advance Treatments For Tuberculosis 13
CSIR Enters Into Co-Development Agreement With TB Alliance 14
TB Alliance Enters into Licensing Agreement with Medicines Patent Pool 15
Novartis Enters into Licensing Agreement with Global Alliance for TB Drug Development for Tuberculosis Drugs 16
TB Alliance Enters Into Licensing Agreement With Fosun Pharma 17
TenNor Acquires Patents from TB Alliance 18
Global Alliance for TB Drug Development, Key Competitors 19
Global Alliance for TB Drug Development, Key Employees 20
Global Alliance for TB Drug Development, Other Locations 22

List of Figures
Global Alliance for TB Drug Development, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Global Alliance for TB Drug Development, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Global Alliance for TB Drug Development, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Global Alliance for TB Drug Development, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Global Alliance for TB Drug Development, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Global Alliance for TB Drug Development, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Global Alliance for TB Drug Development, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Global Alliance for TB Drug Development, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Global Alliance for TB Drug Development:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Genetic Technologies Ltd (GTG)-医療機器分野:企業M&A・提携分析
    Summary Genetic Technologies Ltd (GTG) is a genetic tests company that offers testing products and services to assess sporadic breast cancer risk and cancer development, progression and management. It delivers the offerings by BREVAGen and BREVAGenplus tests. BREVAGen test enables the customers to a …
  • Classic Cosmetics, Inc:企業の戦略・SWOT・財務情報
    Classic Cosmetics, Inc - Strategy, SWOT and Corporate Finance Report Summary Classic Cosmetics, Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Valentino Fashion Group S.p.A:企業の戦略・SWOT・財務情報
    Valentino Fashion Group S.p.A - Strategy, SWOT and Corporate Finance Report Summary Valentino Fashion Group S.p.A - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Civica Group Limited:企業の戦略的SWOT分析
    Civica Group Limited - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • Abreos Biosciences Inc-医療機器分野:企業M&A・提携分析
    Summary Abreos Biosciences Inc (Abreos Biosciences) is a biotechnology company that develops laboratory-based and point-of-care (POC) tests for precision dosing of biologic drugs. The company’s technology platform veritope, allow monitoring of monoclonal antibody drug levels in blood (novel or biosi …
  • Haci Omer Sabanci Holding A.S. (SAHOL):企業の財務・戦略的SWOT分析
    Haci Omer Sabanci Holding A.S. (SAHOL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths a …
  • NetSuite Inc:企業の戦略的SWOT分析
    NetSuite Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • BC Technical Inc-医療機器分野:企業M&A・提携分析
    Summary BC Technical Inc (BC Technical), a subsidiary of MSouth Equity Partners is a medical device company that provides molecular imaging solutions. The company offers spare parts for new and refurbished nuclear medicine equipments for gamma cameras and BC backup server. It provides PET, PET/CT, N …
  • E. Bon Holdings Limited (599):企業の財務・戦略的SWOT分析
    E. Bon Holdings Limited (599) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Targovax ASA (TRVX):企業の財務・戦略的SWOT分析
    Summary Targovax ASA (Targovax) is a developer and commercializer of immunotherapies for the treatment of cancer patients. The company’s lead candidates include TG0, a peptide-based therapeutic anti-cancer vaccine under development for pancreatic cancer; and ONCOS-102 is an adenovirus-based pipeline …
  • America Movil, SA DE C.V.:戦略・SWOT・企業財務分析
    America Movil, SA DE C.V. - Strategy, SWOT and Corporate Finance Report Summary America Movil, SA DE C.V. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Titan Pharmaceuticals Inc (TTNP):企業の財務・戦略的SWOT分析
    Summary Titan Pharmaceuticals Inc (Titan) is a pharmaceutical company that develops therapeutics for the treatment of serious medical disorders. The company develops drugs using ProNeura, a proprietary drug delivery platform, for the treatment of chronic diseases. It product portfolio provides probu …
  • St Ives plc (SIV):企業の財務・戦略的SWOT分析
    St Ives plc (SIV) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • AMETEK Inc (AME):企業の財務・戦略的SWOT分析
    Summary AMETEK Inc (AMETEK) is an electronic products manufacturing company that manufactures electronic instruments and electromechanical devices. The company's products portfolio include medical materials, motion control systems, sub assemblies and connectors, electrical cord reels, gauges, titani …
  • Abu Dhabi Commercial Bank P.J.S.C.:戦略・SWOT・企業財務分析
    Abu Dhabi Commercial Bank P.J.S.C. - Strategy, SWOT and Corporate Finance Report Summary Abu Dhabi Commercial Bank P.J.S.C. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, p …
  • TAT Technologies, Ltd.:企業の戦略・SWOT・財務分析
    TAT Technologies, Ltd. - Strategy, SWOT and Corporate Finance Report Summary TAT Technologies, Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Bonduelle Sca
    Bonduelle Sca - Strategy, SWOT and Corporate Finance Report Summary Bonduelle Sca - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Ormat Technologies Inc (ORA):電力:M&Aディール及び事業提携情報
    Summary Ormat Technologies, Inc. (Ormat), is a vertically integrated company that focuses on the geothermal and recovered energy generation. The company designs, develops, builds, owns, and operates the geothermal and recovered energy generation (REG) power plants. Ormat also supplies geothermal and …
  • ReAssure Ltd:企業の戦略的SWOT分析
    ReAssure Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Pluristem Therapeutics Inc (PSTI):企業の財務・戦略的SWOT分析
    Summary Pluristem Therapeutics Inc (Pluristem) operates as a clinical-stage biotherapy company that focuses on the development of placental-derived cell therapies. Its PLacental eXpanded (PLX) cells are adherent stromal cells that can be administered to patients without tissue or genetic matching. T …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆